fluorogenic dpp4 assay kit (BPS Bioscience)
BPS Bioscience is a verified supplier 
BPS Bioscience manufactures this product 
93
Structured Review
BPS Bioscience
fluorogenic dpp4 assay kit
Fluorogenic Dpp4 Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorogenic+dpp4+assay+kit/DPP4+Assay+Kit/10__1002_slash_slct__202505084-221-19-23
Average 93 stars, based on 6 article reviews
Fluorogenic Dpp4 Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorogenic+dpp4+assay+kit/DPP4+Assay+Kit/10__1002_slash_slct__202505084-221-19-23
Average 93 stars, based on 6 article reviews
fluorogenic dpp4 assay kit - by Bioz Stars,
2026-09
93/100 stars
Images
Related Articles
In Vitro:Article Title: Design, synthesis and evaluation the bioactivities of novel 8‑methoxy-1-azacoumarin-3-carboxamide derivatives as anti-diabetic agents Article Snippet: In this study, a novel series of 8‐methoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid and N-substituted 8‐methoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide derivatives 2–10 were designed, synthesized, and screened for their in vitro α-amylase, α-glucosidase and DPP-4 enzymes resulting in effective anti-diabetic agents.. The research results showed that these compounds had significant inhibitory effects on both α-amylase and α-glucosidase enzymes.. Specifically, compound 4 demonstrated the most potency with IC50 of 30.50±2.67 and 19.98±3.24μM for α-glucosidase and α-amylase activities respectively, which was significantly more powerful than the drug Acarbose (IC50 = 48.97±3.42μM and 16.59±3.78μM). Article Title: Novel Imidazole–Chromen‐2‐One Derivatives: Design, Synthesis, and Biological Evaluation as Potential Antidiabetic and Antioxidant Agents Article Snippet: A series of novel imidazole–chromen-2one derivatives (6–11) were designed, synthesized, and evaluated using an analogbased drug design approach for their potential dual α-glucosidase/ α-amylase inhibitory and anti-inflammatory activities.. In vitro biochemical assays were conducted to assess enzyme inhibition and antioxidant potential.. Among all tested compounds, compound (11) exhibited the most potent α-glucosidase and α-amylase inhibitory effects, with IC50 values comparable to the standard drug Acarbose , indicating significant antidiabetic potential. Recombinant:Article Title: Design, synthesis and evaluation the bioactivities of novel 8‑methoxy-1-azacoumarin-3-carboxamide derivatives as anti-diabetic agents Article Snippet: In this study, a novel series of 8‐methoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid and N-substituted 8‐methoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide derivatives 2–10 were designed, synthesized, and screened for their in vitro α-amylase, α-glucosidase and DPP-4 enzymes resulting in effective anti-diabetic agents.. The research results showed that these compounds had significant inhibitory effects on both α-amylase and α-glucosidase enzymes.. Specifically, compound 4 demonstrated the most potency with IC50 of 30.50±2.67 and 19.98±3.24μM for α-glucosidase and α-amylase activities respectively, which was significantly more powerful than the drug Acarbose (IC50 = 48.97±3.42μM and 16.59±3.78μM). Article Title: Novel Imidazole–Chromen‐2‐One Derivatives: Design, Synthesis, and Biological Evaluation as Potential Antidiabetic and Antioxidant Agents Article Snippet: A series of novel imidazole–chromen-2one derivatives (6–11) were designed, synthesized, and evaluated using an analogbased drug design approach for their potential dual α-glucosidase/ α-amylase inhibitory and anti-inflammatory activities.. In vitro biochemical assays were conducted to assess enzyme inhibition and antioxidant potential.. Among all tested compounds, compound (11) exhibited the most potent α-glucosidase and α-amylase inhibitory effects, with IC50 values comparable to the standard drug Acarbose , indicating significant antidiabetic potential. Enzyme Inhibition Assay:Article Title: Design, synthesis and evaluation the bioactivities of novel 8‑methoxy-1-azacoumarin-3-carboxamide derivatives as anti-diabetic agents Article Snippet: In this study, a novel series of 8‐methoxy-2-oxo-1,2-dihydroquinoline-3-carboxylic acid and N-substituted 8‐methoxy-2-oxo-1,2-dihydroquinoline-3-carboxamide derivatives 2–10 were designed, synthesized, and screened for their in vitro α-amylase, α-glucosidase and DPP-4 enzymes resulting in effective anti-diabetic agents.. The research results showed that these compounds had significant inhibitory effects on both α-amylase and α-glucosidase enzymes.. Specifically, compound 4 demonstrated the most potency with IC50 of 30.50±2.67 and 19.98±3.24μM for α-glucosidase and α-amylase activities respectively, which was significantly more powerful than the drug Acarbose (IC50 = 48.97±3.42μM and 16.59±3.78μM). |
